MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8

R. Glanzman, J. Ren, Phd, R. Dewey, Iii, A. Rynders, K. Ho, Phd, R. Dewey, JR. (Holladay, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 73

Keywords: Disease-modifying strategies, Experimental therapeutics, Parkinson’s

Category: Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Objective: To determine the effects of the nanocatalytic drug, CNM-Au8, on brain energy metabolites in Parkinson’s Disease.

Background: Converging lines of evidence are identifying brain energy dyshomeostasis as a driver of neuronal death in many neurodegenerative diseases, including Parkinson’s Disease (PD). CNM-Au8 is a bioenergetic nanocatalyst, consisting of a suspension of faceted clean-surfaced gold nanocrystals that catalytically improve bioenergetic metabolism in neurons and glial cells. CNM-Au8 catalyzes oxidation of nicotinamide adenine dinucleotide (NADH), an energetic metabolite essential for ATP production, as well as catalyzing the reduction of oxygen radicals.

Method: Seven Tesla 31phosphorous magnetic resonance spectroscopy (31P-MRS) was used to detect levels of energy metabolites including NAD+, NADH, ATP (b-, a-, and g-), and mono- and diester phospholipids in the brains of 12 PD patients. Whole brain spectra was collected in ~600 voxels at a spatial resolution of 2 cm3 with a full volume coil. A partial volume coil was used to determine the NAD+/NADH ratio by imaging the parietal and occipital lobes bilaterally as a single voxel. Imaging was conducted at baseline (BL) and repeated after 12+ weeks.

Results: CNM-Au8 treatment resulted in homeostatic effects on brain bioenergetic metabolites including improvements in the NAD+/NADH ratio (primary endpoint), and normalization of ATP and NAD levels (secondary endpoints). Patients with ATP and NAD levels less than the BL mean significantly increased whole-brain ATP and NAD levels, while patients with BL levels greater than the mean normalized these levels. Importantly, this relationship was highly significant and consistent for several 31P biomarkers: NAD levels, ATP, and several other 31P metabolites (r2 > 0.6; p < 0.01 for each metabolite). We will report 31P-MRS metabolite results, clinical effects on the MDS-UPDRS, and functional correlates between brain metabolic and clinical effects.

Conclusion: Results from this newly completed study are anticipated to provide the first clinical evidence of CNM-Au8 treatment on brain bioenergetic metabolism and support its candidacy as a disease-modifying drug for PD.

A previous preliminary data cut from this trial, consisting of data from 4 MS and 6 PD patients, was presented at the MSVirtual 2020 Meeting.

To cite this abstract in AMA style:

R. Glanzman, J. Ren, Phd, R. Dewey, Iii, A. Rynders, K. Ho, Phd, R. Dewey, JR.. Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8 [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/homeostatic-improvement-of-brain-bioenergetic-metabolism-in-parkinsons-disease-results-from-a-phase-2-repair-pd-clinical-trial-with-cnm-au8/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/homeostatic-improvement-of-brain-bioenergetic-metabolism-in-parkinsons-disease-results-from-a-phase-2-repair-pd-clinical-trial-with-cnm-au8/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley